Search

Displaying results 3561 - 3570 of 7186 in total
  1. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

  2. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    [A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer

    Mixtures: Avmapki Fakzynja Co-packSynonyms: RO-5126766 free base, N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide
  3. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is no longer available in the US market. … Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

  4. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    Also withdrawn from the Canadian and UK markets. … The approved application holder removed Merital capsules from the market on January 23, 1986.

  5. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341 … ] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.

  6. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  7. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

  8. Drug

    Dengue tetravalent vaccine, live

    go.drugbank.com/drugs/DB14764
    ApprovedInvestigational

  9. Drug

    Streptozocin

    go.drugbank.com/drugs/DB00428
    ApprovedInvestigational

    An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.

    Synonyms: N-D-Glucosyl-(2)-N'-nitrosomethylurea, N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
  10. Drug

    Levobupivacaine

    go.drugbank.com/drugs/DB01002
    ApprovedInvestigationalWithdrawn

    Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. … Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine.